The approval makes Biocon’s pertuzumab the first biosimilar to receive EC marketing authorisation under the European Medicines Agency’s (EMA) new tailored clinical approach
The post Biocon's Pebrilzo gets EU nod for HER2-positive breast cancer treatment appeared first on Home Page.
